[1] Ozkaya Akagunduz O, Ergen A, Erpolat P, et al.Local recurrence outcomes after breast conserving surgery and adjuvant radiotherapy in ductal carcinoma in situ of the breast and a comparison with ECOG E5194 study[J]. Breast, 2018,42:10-14. [2] Barrio AV, Van Zee KJ.Controversies in the Treatment of Ductal Carcinoma in Situ[J]. Annu Rev Med, 2017,68:197-211. [3] 马国树,兰占儒,薛敏,等.钼靶X线和超声联合检查诊断浆细胞性乳腺炎与病理的一致性分析[J].宁夏医学杂志,2021,43(2):183-185. [4] 杜洪勇,于伟峰,姜志海.超声与钼靶摄影诊断乳腺导管原位癌的对照研究[J].影像研究与医学应用,2022,6(1):115-117. [5] Ross DS,Hoda SA.Microinvasive (T1mic) lobular carcinoma of the breast:clinicopathologic profile of 16 cases[J]. Am J Surg Pathol,2011,35(5):750-756. [6] Caswell-Smith P,Wall M.Ductal carcinoma insitu: Is core needle biopsy ever enough?[J]. J Med Imaging Radiat Oncol,2017,61(1):29-33. [7] 曹威,何英剑,李金锋,等.超声引导下空芯针穿刺活检诊断的乳腺导管原位癌病理学低估的危险因素分析[J].中国癌症杂志,2020,30(3):217-223. [8] 赵梦,王冲,朱强,等.非哺乳期乳腺炎的危险因素分析及预测模型建立[J].中国医刊,2021,56(5):497-500. [9] 中华医学会外科学分会乳腺外科学组.早期乳腺癌保留乳房手术中国专家共识(2019版)[J].中华外科杂志,2019,57(2):81-84. [10] 李志伟,郑新宇. 乳腺导管原位癌治疗的争议与共识[J].中国实用外科杂志,2018,38(11):1265-1270. [11] 吴炅,王永胜,柳光宇,等. 保留乳房治疗专家共识(2020年版)[J]. 中国癌症杂志,2020,30(11):912-968. |